Industry News
Biotechnology Industry News
Rather than leave the work of…
Rather than leave the work of developing relationships in China to individual companies, the firm launched an initiative called RA Capital Swiftbridge in mid-2025.
Innovent Biologics has reported a…
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.
Fierce sat down with Cabaletta’s…
Fierce sat down with Cabaletta's executives at EULAR to discuss their approval timeline and which areas of development they feel like they have a head start.
Alnylam has partnered with the…
Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design.
Capital is tighter and…
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
PhaseV CEO Raviv Pryluk explains…
PhaseV CEO Raviv Pryluk explains how AI is reshaping trial design and execution.
AI is accelerating discovery, but…
AI is accelerating discovery, but only when paired with expert insight and trusted data. Hear how leaders are rethinking decision-making in biopharma.
Regeneron has expanded its…
Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells the potential value of the
Unlearn founder and head of AI,…
Unlearn founder and head of AI, Aaron Smith, on how digital twins are moving from trial simulation into the full chain of decisions sponsors make — and what regulators need to see along the way.
Ascidian Therapeutics and Eli…
Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to discover and develop RNA exon editing therapeutics for genetic kidney diseases.
Travere Therapeutics has set its…
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the clinic.
Anti-aging startup NewLimit is…
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
Fulcrum Therapeutics has scrapped…
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market.
Abivax has raised the efficacy bar…
Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a reported takeover
Cardiff Oncology has shared…
Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the biotech prepares to enter pivotal development.
Takeda and Innovent’s long-term…
Takeda and Innovent's long-term follow-up data from an early study of their collaborative PD-1/IL-2 bispecific colors the "tremendous potential" of the asset, Takeda's P.K. Morrow said in an interview.
While Revolution Medicines…
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same with a different vexing target that drives a
Early ASCO 2026 data show strong…
Early ASCO 2026 data show strong responses and improved safety with mesutoclax in high-risk MDS and AML. Hear what it may mean for treatment.
For patients with a rare cancer…
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first
Strategy matters—but execution…
Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.